Abstract
Von Willebrand disease (VWD), the most common inherited bleeding disorder, is caused
by deficiency or dysfunction in von Willebrand factor. Assessment of hemorrhagic symptoms
is essential for early diagnosis, although bleeding histories are taken in a nonstandardized
manner. Validated bleeding assessment tools provide objectivity in evaluating bleeding
patterns of females at menarche and may improve provider confidence in screening for
VWD. Utilizing a pretest/posttest design, in this project we implemented and evaluated
the use of a pediatric bleeding questionnaire in eight pediatric primary care clinics
for 3 months. Results indicate improved provider knowledge, confidence, and skills
after implementation. The importance and quality of the tool were rated highly by
the providers, while the ease of use was rated low. Providers were satisfied with
the practice change and believed that it improved their clinical abilities. The use
of this tool can improve VWD screening in this practice setting.
Key Words
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Journal of Pediatric Health CareAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- von Willebrand's disease: A report from a meeting in the Åland islands.Haemophilia. 2012; 18: 1-13
- Evaluation of the diagnostic utility for von Willebrand disease of a pediatric bleeding questionnaire.Journal of Thrombosis and Haemostasis. 2009; 7: 1418-1421
- Identification and management of women with inherited bleeding disorders: A survey of obstetricians and gynaecologists in the United Kingdom.Haemophilia. 2006; 12: 405-412
- Menstruation in girls and adolescents: Using the menstrual cycle as a vital sign. American Academy of Pediatrics Committee on Adolescence, American College of Obstetricians and Gynecologists Committee on Adolescent Health Care.Pediatrics. 2006; 118: 2245-2250
- Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease (MCMDM-1VWD).Blood. 2007; 109: 112-121
- Blood disorders and blood safety: Bleeding and clotting.2014 (Retrieved from)
- The power of a standardized bleeding score in diagnosing paediatric type 1 von Willebrand's disease and platelet function defects.Haemophilia. 2011; 17: 223-227
- von Willebrand disease (VWD): Evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA).Haemophilia. 2008; 14: 171-232
- The discriminant power of bleeding history for the diagnosis of type 1 von Willebrand disease: An international, multicenter study.Journal of Thrombosis and Haemostasis. 2005; 3: 2619-2626
- Low von Willebrand factor: Sometimes a risk factor and sometimes a disease.Hematology/the Education Program of the American Society of Hematology. 2009; : 106-112
- Prospective evaluation of the clinical utility of quantitative bleeding severity assessment in patients referred for hemostatic evaluation.Journal of Thrombosis and Haemostasis. 2011; 9: 1143-1148
- A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: Results from a multicenter European study (MCMDM-1 VWD).Journal of Thrombosis and Haemostasis. 2006; 4: 766-773
Biography
Joana Duran, Student, School of Nursing, Duke University, Durham, NC.
Biography
Joseph L. Lasky III, Chief, Division of Pediatric Hematology/Oncology, Harbor UCLA Medical Center, Torrance, CA.
Biography
Cheryl Rodgers, Assistant Professor, School of Nursing, Duke University, Durham, NC.
Article info
Publication history
Published online: November 21, 2015
Footnotes
Conflicts of interest: Joana Duran holds a position in the Department of Scientific & Medical Affairs at Octapharma USA, Inc. The other authors have no conflicts of interest to report.
Identification
Copyright
Copyright © 2015 by the National Association of Pediatric Nurse Practitioners. Published by Elsevier Inc. All rights reserved.
